Thursday, 15 October 2026European Markets

VITURA Stock Bearish By 18% In The Last 5 Sessions

Loading stream...

(vianews) - shares of vitura (cac 40: vtr.pa) fell by a staggering 18.03% in 5 sessions from €24.4 to €20.00 at 04:10 est on wednesday, after five sequential sessions in a row of losses. cac 40 is jumping 1.86% to €7,141.57, following the last session's upward trend.

about vitura

created in 2006, cegereal is a listed property company that invests in prime office properties in greater paris. the total value of the portfolio was estimated at €1,460 million at june 30, 2020 (excluding transfer duties). thanks to its strong commitment to environmental, social and governance issues, cegereal achieved first place among listed companies in europe in the 2019 global real estate sustainability benchmark (gresb) ranking. its entire portfolio has achieved nf hqetm exploitation and breeam in-use international certification. cegereal is a reit listed on euronext paris since 2006, in compartment b (isin: fr0010309096). the company had a market capitalization of €398 million at november 5, 2020.

earnings per share

as for profitability, vitura has a trailing twelve months eps of €1.71.

pe ratio

vitura has a trailing twelve months price to earnings ratio of 11.67. meaning, the purchaser of the share is investing €11.67 for every euro of annual earnings.

more news about vitura (vtr.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com